Loading clinical trials...

Integrated Treatment of Marijuana Abuse for HIV+ Youth | Clinical Trials | Clareo Health

COMPLETEDNA

Integrated Treatment of Marijuana Abuse for HIV+ Youth

Integrated Treatment of Alcohol and/or Marijuana Abuse for HIV-Infected Youth - Phase I

NCT00683488•University of North Carolina, Chapel Hill

Summary

This is an exploratory study that will adapt and test a combined cognitive behavioral treatment and contingency management intervention for alcohol and/or marijuana abuse for use in HIV-infected adolescents.

Eligibility

Age

16 - 24 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adolescents between the ages of 16-24 years (inclusive) at the time of informed consent/assent as determined by medical record review or verbal verification from referring professional
•HIV-infected and aware of their status as documented by medical record review or verbal verification from referring professional
•Receives services at one of the three participating ATN clinic site or their community partners
•A score of 2 or greater on the CRAFFT indicating possible alcohol or marijuana use problem or abuse
•Alcohol and/or Marijuana Use or Abuse Disorder as indicated by the SSPQ-X
•Appropriate for an outpatient or intensive outpatient level of care in accordance with the American Academy of Child and Adolescent Psychiatry practice parameters as decided by site mental health provider in consultation with Drs. Brown and Esposito-Smythers
•English-speaking
•Ability and willingness to provide informed consent/assent for study participation
•Satisfactorily understands the nature of the study and the informed consent process as documented by the Consent Form Comprehension Assessment Questionnaire

Exclusion Criteria

•Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder)
•Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior)
•Intoxicated or under the influence of alcohol or other substances at the time of study entry

Locations (3)

Childrens Hospital of Los Angeles

Los Angeles, California, United States

Mount Sinai Medical Center

New York, New York, United States

Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

April 1, 2008

Primary Completion Date

August 1, 2010

Completion Date

April 1, 2011

Last Updated

March 6, 2017

Enrollment

ACTUAL participants

Conditions

HIV Infections

Interventions

Focus Group

BEHAVIORAL

First Intervention Trial

BEHAVIORAL

Intervention Trial 2

BEHAVIORAL

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITINGPHASE3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Integrated Treatment of Marijuana Abuse for HIV+ Youth

Inclusion Criteria

Exclusion Criteria

Skeletal Muscle Energetics and Fatiguability in Older Individuals

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

Comprehensive HIV and Harm Prevention Via Telehealth